Diabetic neuropathy. Insulin-dependent diabetes mellitus with neurological complications
Conditions
Interventions
Intervention 1: The first intervention group will receive 100 mg of Neurotec capsules (Nano hayat products) per month for one month. Intervention 2: The second intervention group, gabapentin (a produc
Treatment - Drugs
The first intervention group will receive 100 mg of Neurotec capsules (Nano hayat products) per month for one month
The second intervention group, gabapentin (a product of Sobhan Pharmaceutical Company) will start for one month at a dose of 100 mg and, if necessary and patient tolerate, will increase up to 300 mg.
Sponsors
Vice chancellor for research of Kermanshah University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria : People with diabetes; People who have complain from sensory symptoms, paresthesia or pain; Informed consent. Exclusion criteria:Patients suffering from other diseases such as uremia that can cause neuropathy; Patients with contraindications to the drug such as pregnancy; patients who have taken other drugs to control neuropathic symptoms
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sensory symptoms. Timepoint: At the end of the sixth and tenth weeks of treatment,. Method of measurement: Question from patient and visual observation (VAS). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSepideh Seydi
Kermanshah University of Medical Sciences
Outcome results
None listed